Source/Upstream News·Chongqing Business Daily Chief Reporter Liu Yong
Editor/Zhong Yingtong
html On December 5, Chongqing Zhifei Bio (300122) continued to be strong, closing at 195.97 yuan, up 6.12%, with a total market value of 313.552 billion yuan, firmly ranking as the largest Chongqing stock market value.During the session, Zhifei Bio once exceeded 200 yuan, reaching 203.80 yuan, with a market value of 326.08 billion yuan. Both the intraday price and closing price hit a record high. The previous historical high price was 194.21 yuan set on July 30 last year. Zhifei Bio is also the highest-priced stock in Chongqing.
Upstream News. Chongqing Business Daily reporter learned that Zhifei Biotech has ranked among the top five in the GEM in total market value, after CATL (869.9 billion yuan), Golden Dragon Fish (616.4 billion yuan), Mindray Medical (587.6 billion yuan), and Aier Eye Hospital (338.7 billion yuan).
reached a high price of 203.80 yuan during the session and
It is understood that Zhifei Bio closed at 184.67 yuan on February 4. On February 5, Zhifei Bio opened at 185.10 yuan, which is also the lowest price of the day. The highest during the session once hit 203.80 yuan, with a total market value of 326.08 billion yuan, and finally closed at 195.97 yuan. The corresponding dynamic price-to-earnings ratio was 101.73 times, an increase of 6.12%, a trading volume of 308,000 lots, an amplitude of 10.13%, a turnover rate of 6.042 billion yuan, a turnover rate of 3.42%, and a total market value of 313.552 billion yuan, firmly ranking as the largest Chongqing stock market value. Zhifei Bio closed at 147.91 yuan on December 31 last year, with a cumulative increase of 32.49% this year.
Tianyan Check APP shows that Zhifei Bio is registered in Jiangbei District, Chongqing. The legal representative Jiang Rensheng was listed on the Shenzhen GEM on September 28, 2010. It has an initial public offering of 40 million shares, with an issue price of 37.98 yuan per share, and a total share capital of 400 million shares after issuance. After increasing distribution, the total share capital is 1.6 billion shares.
In the five trading days this week, according to Oriental Wealth data, the net inflow of main funds of Zhifei Biologics were RMB 96.95 million, RMB 6.49 million, RMB 314 million, RMB -17.25 million, and RMB 96.02 million, respectively.
html On December 5, the biological vaccine stocks rose across the board, and Shuanglin Bio, Sinopharm , Hualan Biotechnology, etc. also rose sharply.net profit increased by 40% in the first three quarters of last year
news, on the 2nd and 3rd, Gao Fu and others of the Chinese Center for Disease Control and Prevention released the protective effect of the domestic inactivated new crown vaccine (BBIBP-CorV inactivated new crown vaccine in Beijing Institute of Biological Products) and the domestic recombinant protein subunit new crown vaccine ( Zhifei Bio and the Chinese Academy of Sciences) on the new South African variant (SARS-CoV-2 variant of concern (VOC)501Y.V2). The results show that although the neutralization effect of these two vaccinators on the new South African variants has slightly decreased, most of the neutralization activity is still retained, suggesting that these two vaccines still have protective effects on the new South African variants.
Zhifei Bio2020 third quarter report showed that it achieved operating income of 11.05 billion yuan, a year-on-year increase of 44.14%; net profit attributable to shareholders of listed companies was 2.479 billion yuan, a year-on-year increase of 40.59%; net profit after deducting non-operating items was 2.483 billion yuan, an increase of 38.11%, and earnings per share was 1.5491 yuan, maintaining the momentum of continuous and rapid growth in performance. The net cash flow generated by operating activities was 2.468 billion yuan, an increase of 338.43% year-on-year. Among them, from July to September, the company achieved operating income of 4.056 billion yuan, a year-on-year increase of 54.37%; net profit attributable to shareholders of listed companies was 974 million yuan, a year-on-year increase of 58.13%, and net cash flow generated by operating activities was 2.068 billion yuan, a year-on-year increase of 417.03%. In the first half of 2020, the company's revenue and net profit increased by 38.80% and 31.18% respectively. Zhifei Biological 2020 annual report is scheduled to be disclosed on April 20 this year.
